Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • VIVO Cannabis™ (VIVIO) completes first shipment of EU-GMP medical grade cannabis to Beacon Medical Germany GmbH
  • Beacon Medical™ product will undergo full range quality testing for market release in a German GMP-certified specialized lab to ensure the highest product quality
  • VIVO Cannabis™ is recognized for trusted, premium cannabis products and services
  • VIVO Cannabis’s (VIVO) is trading at C$0.09 at 1:46 pm ET

VIVO Cannabis’s (VIVO) subsidiary ABcann Medicinals has completed its first shipment of EU-GMP certified Canadian dried flower medical cannabis into Europe.

This follows ABcann Medicinals receiving EU-GMP certification in March 2021, and VIVO’s wholly-owned German subsidiary Beacon Medical Germany GmbH receiving an import licence from Germany’s Brandenburg health authority, the Landesamt für Arbeitsschutz, Verbraucherschutz und Gesundheit, as well as its first import permit from Germany’s BfArM, the Federal Institute for Drugs and Medical Devices in July 2021.

“This is a monumental milestone for VIVO. We thank our team for their dedication over the last few years to get us to this point,” commented Ray Laflamme, Canna Farms’ Co-Founder and VIVO’s Chief Executive Officer.

“We are excited to kick-off VIVO’s commercial business in Germany, as our second international medical cannabis market after Australia. We are confident that our products will be just as successful with patients in Germany as they have proved to be with patients in Australia,” added Laflamme.

Beacon Medical Germany GmbH will be responsible for commercialization in Germany. “We look forward to introducing premium quality Beacon Medical™ products to physicians, pharmacists and patients in Europe,” commented Andreas Sander, VIVO’s President of European Operations.

Beacon Medical™ product will undergo full range quality testing for market release in a German GMP-certified specialized lab to ensure the highest product quality and patient safety.

VIVO Cannabis™ is recognized for trusted, premium cannabis products and services. It holds production and sales licences from Health Canada and operates world-class indoor and seasonal airhouse cultivation facilities.

VIVO Cannabis’s (VIVO) is trading at C$0.09 at 1:46 pm ET.

More From The Market Herald

" Choom (CSE:CHOO) reports a profitable first quarter of 2022

Choom (CHOO) has announced results for Q1 2022 highlighted by net income of C$5.07M.

" Nextleaf (CSE:OILS) continuing to expand Glacial Gold brand

Nextleaf Solutions (OILS) announced its Glacial Gold brand of cannabis has been picked up by additional provincial distribution authorities.

" Simply Better Brands (TSXV:SBBC) announces third quarter 2021 results

Simply Better Brands (SBBC) experienced year-over-year growth this quarter, with higher revenue and gross margin compared to Q3 2020.

" Nabis Holdings (CSE:NAB) noteholders approve plan for the repurchase and de-listing of notes

Nabis Holdings (NAB) announces that 100 per cent of votes cast were in favour of the previously announced repurchase of all notes.